Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
To obtain a patient specific understanding of response to treatment with onabotulinumtoxinA
by collecting and correlating pre and post treatment subject specific history, clinical
outcomes, and histological changes.
Phase:
Phase 4
Details
Lead Sponsor:
Cady, Roger, M.D.
Collaborator:
Allergan
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA